Clinical Trials Logo

Advanced Malignant Tumors clinical trials

View clinical trials related to Advanced Malignant Tumors.

Filter by:

NCT ID: NCT05354076 Recruiting - Clinical trials for Advanced Malignant Tumors

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Start date: March 1, 2000
Phase: Phase 2
Study type: Interventional

To study the correlation between the content of natural IgM in patients' blood samples and liposomal doxorubicin for clinical use, and to explore the possibility of using natural IgM content to guide clinical accurate medication.

NCT ID: NCT05235542 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Start date: July 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors

NCT ID: NCT05229497 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Start date: May 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors

NCT ID: NCT05223231 Recruiting - Clinical trials for Advanced Malignant Tumors

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.

NCT ID: NCT05214482 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study of AK112 in Advanced Malignant Tumors

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors

NCT ID: NCT05198817 Enrolling by invitation - Clinical trials for Advanced Malignant Tumors

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Start date: February 22, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.

NCT ID: NCT05193721 Active, not recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.

NCT ID: NCT05110807 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Start date: January 5, 2022
Phase: Phase 1
Study type: Interventional

TQB3617 is a bromodomain and extra-terminal (BET) inhibitor that can competitively bind to bromodomains (BRDs) with Acetylated lysine(Kac) and block or partially block the role of KAc in subsequent gene transcription and regulation of chromatin structure, thereby playing an anti-tumor role.

NCT ID: NCT05082545 Completed - Clinical trials for Advanced Malignant Tumors

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Start date: November 23, 2021
Phase: Phase 1
Study type: Interventional

This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.

NCT ID: NCT04980690 Recruiting - Clinical trials for Advanced Malignant Tumors

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

Start date: August 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.